Policy & Compliance FDA Mifepristone Safety Review Advances as Louisiana Court Deadline Nears
Key Takeaways The Food and Drug Administration (FDA) is moving forward with its newest safety review of Mifepristone as an October court deadline approaches in ongoing litigation that could influence



